Company profile: Stada
1.1 - Company Overview
Company description
- Provider of pharmaceuticals and non-prescription consumer health products, operating on three pillars: OTC consumer healthcare, generics, and specialty pharmaceuticals. Sells products in over 120 countries, including acetaminophen, lactulose, Grippostad-C, Vitaprost, Cardiomagnyl, Xefocam Rapid, Aqualor, Edarbi, and Levomekol.
Products and services
- Aqualor: A multi-format nasal irrigation and cleansing solution that cleans nasal passages for children and adults, available in various forms tailored to different nasal spray types
- Cardiomagnyl: A dual-component tablet combining acetylsalicylic acid and magnesium hydroxide to prevent thrombosis and treat cardiovascular conditions, supplied in tablet-form for oral use
- Edarbi: A tablet-based medication used for the treatment of hypertension, oral tablet format intended for managing high blood pressure conditions
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Stada
Procemsa
HQ: Italy
Website
- Description: Provider of development, production and packaging services for food supplements, medical devices and cosmetics, supported by state-of-the-art production facilities and a Research and Development Center, offering regulatory support, clinical trial services and stability studies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Procemsa company profile →
CoGenesys
HQ: United States
Website
- Description: Provider of peptide- and protein-based medicine development for cancer, cardiovascular, metabolic, infectious, autoimmune, and CNS diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CoGenesys company profile →
Cequent Pharmaceuticals
HQ: United States
Website
- Description: Provider of TransKingdom RNA interference (tkRNAi) therapeutics using non-pathogenic bacteria to deliver RNAi into cells to silence disease-causing genes, with pre-clinical drug candidates for colon cancer prevention and inflammatory bowel disease, targeting a wide range of human diseases from inflammatory conditions to cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cequent Pharmaceuticals company profile →
Bliss Biopharma
HQ: China
Website
- Description: Provider of tumor-targeting and immunotherapy therapeutics, focused on antibody-drug conjugates (ADCs). Offers BB-1701, an anti-HER2 ADC in international multi-center trials for HER2-positive solid tumors, and a diverse ADC pipeline in preclinical and clinical stages. Operates in-house, GMP-compliant antibody and ADC manufacturing to support clinical development and early commercialization.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bliss Biopharma company profile →
Adnexus Therapeutics
HQ: United States
Website
- Description: Provider of discovery and development of Adnectins, a novel proprietary class of targeted biologics designed to block or stimulate therapeutic targets to fight diseases across a broad range of therapeutic areas; operates as a Bristol-Myers Squibb R&D company in the United States.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Adnexus Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Stada
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Stada
2.2 - Growth funds investing in similar companies to Stada
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Stada
4.2 - Public trading comparable groups for Stada
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →